Nov 21 (Reuters) - Eli Lilly ( LLY ) hit $1 trillion in

market value on Friday, making it the first drugmaker to enter

the exclusive club dominated by tech giants and underscoring its

rise as a weight-loss powerhouse.

Here are some reactions to Lilly joining the trillion dollar

club:

EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS

"The current valuation points to investor confidence in the

longer-term durability of the company's metabolic health

franchise. It also suggests that investors prefer Lilly over

Novo in the obesity arms race. Taking a step back, we're also

seeing money rotate into the sector as investors may be worried

about an AI bubble."

HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY

SHAREHOLDER HAVERFORD TRUST

"Investors have historically liked secure earnings growth

and (Eli Lilly ( LLY )) is the only large cap pharma that has that kind

of earnings profile."